The lancet oncology
-
The lancet oncology · Feb 2010
Randomized Controlled Trial Multicenter StudyIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma. ⋯ Bristol-Myers Squibb.
-
The lancet oncology · Feb 2010
Cancer survival in Africa, Asia, and Central America: a population-based study.
Population-based cancer survival data, a key indicator for monitoring progress against cancer, are not widely available from countries in Africa, Asia, and Central America. The aim of this study is to describe and discuss cancer survival in these regions. ⋯ Association for International Cancer Research (AICR; St Andrews, UK), Association pour la Recherche sur le Cancer (ARC, Villejuif, France), and the Bill & Melinda Gates Foundation (Seattle, USA).
-
The lancet oncology · Feb 2010
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.
Analyses of microRNA expression profiles have shown that many microRNAs are expressed aberrantly and correlate with tumorigenesis, progression, and prognosis of various haematological and solid tumours. We aimed to assess the relation between microRNA expression and progression and prognosis of gastric cancer. ⋯ National Cancer Institute.